Tao Synergies Inc. (TAOX) — 8-K Filings

8-K Filings (17)

• TAO Synergies Inc. Files 8-K: Director Changes & Officer Appointments — Dec 19, 2025 Risk: medium
  TAO Synergies Inc. filed an 8-K on December 19, 2025, reporting on events from December 18, 2025. The filing covers the departure of directors, election of new
• TAO Synergies Inc. Files 8-K: Material Agreement & Equity Sales — Oct 14, 2025 Risk: medium
  TAO Synergies Inc. announced on October 13, 2025, that it entered into a material definitive agreement. The company also disclosed unregistered sales of equity
• TAO Synergies Inc. Files 8-K: Board Changes & Compensation — Aug 29, 2025 Risk: medium
  TAO Synergies Inc. announced on August 26, 2025, a change in its board of directors and executive compensation arrangements. The filing also includes informatio
• TAO Synergies Inc. Appoints New CMO and Directors — Aug 8, 2025 Risk: low
  TAO Synergies Inc. announced on August 6, 2025, several key executive and board changes. Dr. Jonathan S. Roth, previously a director, has been appointed as the
• TAO Synergies Inc. Files 8-K, Relocates Offices — Aug 6, 2025 Risk: low
  On August 6, 2025, TAO Synergies Inc. (formerly Synaptogenix, Inc. and NEUROTROPE BIOSCIENCE, INC.) filed an 8-K report. The filing indicates a change in its pr
• TAO Synergies Inc. Files 8-K — Jul 17, 2025 Risk: low
  TAO Synergies Inc. filed an 8-K on July 17, 2025, reporting on other events and financial statements. The company, formerly known as Synaptogenix, Inc. and Neur
• TAO Synergies Inc. Files 8-K with Executive Changes — Jun 27, 2025 Risk: medium
  TAO Synergies Inc. announced on June 26, 2025, several key executive changes and compensatory arrangements. The company also reported amendments to its articles
• Synaptogenix, Inc. Files 8-K — Jun 24, 2025 Risk: low
  Synaptogenix, Inc. filed an 8-K on June 24, 2025, reporting on other events and financial statements. The company, formerly known as Neurotrope Bioscience, Inc.
• Synaptogenix Announces Material Agreement, Officer Changes — Jun 9, 2025 Risk: medium
  Synaptogenix, Inc. announced on June 4, 2025, the entry into a material definitive agreement. The company also reported on the departure of directors or certain
• Synaptogenix Files 8-K: Director/Officer Changes & Financials — Dec 20, 2024 Risk: medium
  Synaptogenix, Inc. filed an 8-K on December 20, 2024, reporting events as of December 16, 2024. The filing indicates changes related to directors and officers,
• Synaptogenix Files 8-K on Security Holder Votes — Dec 6, 2024 Risk: low
  Synaptogenix, Inc. filed an 8-K on December 6, 2024, to report on matters submitted to a vote of its security holders. The filing does not contain specific deta
• Synaptogenix, Inc. Changes Certifying Accountant — Oct 4, 2024 Risk: low
  Synaptogenix, Inc. filed an 8-K on October 4, 2024, reporting a change in its certifying accountant as of September 30, 2024. The company previously operated un
• Synaptogenix, Inc. Files 8-K for Corporate Updates — Sep 13, 2024 Risk: low
  Synaptogenix, Inc. filed an 8-K on September 13, 2024, reporting on events that occurred on September 12, 2024. The filing indicates changes to the company's Ar
• Synaptogenix, Inc. Files 8-K: Material Agreement & Equity Sales — Sep 11, 2024 Risk: medium
  Synaptogenix, Inc. announced on September 10, 2024, that it entered into a Material Definitive Agreement. The company also reported on unregistered sales of equ
• Synaptogenix Changes Fiscal Year End — Sep 9, 2024 Risk: low
  Synaptogenix, Inc. filed an 8-K on September 9, 2024, reporting a change in its fiscal year end to December 31st. This change was effective as of September 3, 2
• Synaptogenix Appoints Dr. David R. Spiegel as CMO — Jun 21, 2024 Risk: medium
  Synaptogenix, Inc. announced on June 20, 2024, the appointment of Dr. David R. Spiegel as Chief Medical Officer. Dr. Spiegel brings extensive experience in neur
• Synaptogenix Files 8-K with Corporate Updates — Apr 4, 2024 Risk: low
  Synaptogenix, Inc. filed an 8-K on April 4, 2024, reporting amendments to its articles of incorporation or bylaws, other events, and financial statements/exhibi

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX